FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver
about
Endocrine fibroblast growth factors 15/19 and 21: from feast to famineFibroblast Growth Factor Signaling in Metabolic RegulationControversies in the Mechanism of Total Parenteral Nutrition Induced PathologyFundamentals of FGF19 & FGF21 action in vitro and in vivoInhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in miceFGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathwaysLXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouseThe metabolic syndromeβ-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue.Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations.The heteromeric organic solute transporter, OSTα-OSTβ/SLC51: a transporter for steroid-derived moleculesFibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions.The Fibroblast Growth Factor signaling pathwayActivation of Liver FGF21 in hepatocarcinogenesis and during hepatic stressPeripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.Effects on transcriptional regulation and lipid droplet characteristics in the liver of female juvenile pigs after early postnatal feed restriction and refeeding are dependent on birth weight.New genetic loci link adipose and insulin biology to body fat distribution.Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs.Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic DiseasesMetabolic effects of intestinal absorption and enterohepatic cycling of bile acids.Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats.Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity.FGF19 action in the brain induces insulin-independent glucose loweringSelective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob miceBitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice.Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibitionPubertal high fat diet: effects on mammary cancer development.Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways.The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease.Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance.Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice.Genome-wide RNA-Seq analysis of breast muscles of two broiler chicken groups differing in shear force.Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.
P2860
Q24629260-5A0B26CC-EDC4-4753-94D4-1DD56662458CQ26772751-3F0A7235-98A0-4A3D-8051-A1C276A8F64CQ26865276-BA3C4960-7232-499F-9704-BC673370F086Q28729024-7C82682D-52DE-4EB8-94F3-7034C6F0EAB4Q28729212-DBC418AE-DFD6-416F-99CB-B38E781E3AF2Q28741802-32E84D2B-9EB5-4D3D-8494-34AFBE5EE6DBQ30491802-46776FAF-AC40-4D64-A1A7-A9D18815412AQ33569142-0BA92439-9373-4164-9510-0454FCCEAED9Q33578966-C2F84F36-B088-4F41-A966-A6CF93B8D006Q34258918-FE0152B6-7151-432A-AC87-A643A7EC29BEQ34333722-59676F58-3379-4D4A-A614-7DE8358A12B0Q34430978-5B301F96-1BEB-4BFF-82A0-5A01AF15F3D5Q34467171-3025DF1C-5458-4A9A-A685-C947F4F96E35Q34670357-F34B806C-A730-4349-AD70-9505CC4345A9Q34901544-256DD010-DCC0-4E8B-B9FA-29DA7A372816Q35048017-17E4BADA-D1E5-47DA-AFBD-229381A806FBQ35114362-00E5B413-9501-43C2-A013-BE8BC9E22022Q35925160-C07DE7C7-64E7-4D79-A4A1-BE94965BBD02Q36107291-5FF2685F-4ADC-45A4-8102-8909E653D043Q36237911-A6E55082-CB5B-4724-81E5-F1593175BE05Q36486182-17567E1A-8CCB-4A43-8BAB-FCC8D8522FA3Q36623086-CF5964FC-9B99-4E30-BE33-28B854DF8DC3Q37259301-574EFA02-6E8D-48E7-B1A7-166ADB741C9FQ37303131-B99B0A2D-3002-4E7F-B745-6339B844AEC1Q37550329-5C923AE1-A659-4E97-A628-1BDAD6F120EDQ37631288-8F29D586-7D6F-4934-B3AE-1F88B050510BQ37690070-47B5FB4B-85F9-4506-8ADE-475E89C758EFQ37699321-34BA3EE9-4494-40DD-92CA-0461335623A0Q37733708-23D2184A-5650-4BAB-A979-5236DE76E2BFQ38176101-03967B0A-0F43-48A9-A651-714A215517BAQ38178585-F4449BCD-40E8-45D9-9895-BAB610F62A6EQ38303270-891EF27B-B8CB-4590-BE3C-76B935F3B1A7Q38315303-722D60F5-049A-4180-A9A3-A6BD47583C6EQ38325739-FA11826E-E03C-41DC-8AAA-6391E16748C5Q39262148-95B36683-277B-4769-A2CF-2A77B4C343C6Q39374896-F44C8CEF-BF4B-43C0-88DD-BD571BEEF0DFQ39676210-3275DCBD-49CE-4B0A-B018-EB2478FC31F8Q39906684-B36168E4-AFB7-4469-8B10-B283ECFC4EBBQ40291650-A092CF3D-A499-4DC4-BA57-E086C2617E4FQ41839560-05C97DF8-C2AE-49F3-908F-71556EA57DE1
P2860
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver
description
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im Oktober 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/10/01)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/10/01)
@nl
наукова стаття, опублікована в жовтні 2007
@uk
مقالة علمية (نشرت في أكتوبر 2007)
@ar
name
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@ast
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@en
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@nl
type
label
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@ast
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@en
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@nl
prefLabel
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@ast
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@en
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@nl
P2093
P921
P356
P1433
P1476
FGFR4 prevents hyperlipidemia ...... h-fat diet induced fatty liver
@en
P2093
Chaofeng Yang
Chengliu Jin
Wallace L. McKeehan
Xinqiang Huang
Yongde Luo
P304
P356
10.2337/DB07-0648
P407
P577
2007-10-01T00:00:00Z